CHEK2 I157T associates with familial and sporadic colorectal cancer

被引:67
|
作者
Kilpivaara, O.
Alhopuro, P.
Vahteristo, P.
Aaltonen, L. A.
Nevanlinna, H.
机构
[1] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00029 Helsinki, Finland
[2] Univ Helsinki, Dept Med Genet, Helsinki, Finland
关键词
D O I
10.1136/jmg.2005.038331
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Background: Recently, a functionally defective CHEK2 variant I157T has been proposed to associate with an increased risk of several types of cancer. We investigated the CHEK2 I157T variant for colorectal cancer (CRC) predisposition in a large population based study including a significant number of familial CRC cases. Methods: We screened the CHEK2 I157T variant in a population based series of 1042 Finnish CRC patients using restriction fragment length polymorphism. Mutation status was studied for correlation with clinical characteristics and family history of CRC and other cancers. Results: The frequency of CHEK2I157T was significantly higher in CRC patients (7.8%, 76/972) than in healthy population controls (5.3%, 100/1885) (OR = 1.5, 95% CI 1.1 to 2.1, p = 0.008). The significant association of CHEK2 I157T with CRC was observed among patients with ( 10.4%, 14/135) and without (7.4%, 62/837) a family history of CRC (OR = 2.1, 95% CI 1.1 to 3.7, p = 0.01; OR= 1.4, 95% CI 1.0 to 2.0, p = 0.03; respectively). A trend towards higher variant frequency was also noted among patients with multiple primary tumours and a family history of any cancer. Conclusions: CHEK2 I157T associates with an increased risk of CRC: the association was observed both among familial and sporadic CRC patients. Furthermore, the higher frequency of I157T among patients with multiple primary tumours as well as those with a family history of any cancer supports a role for CHEK2 I157T as a susceptibility allele for multiple cancer types.
引用
收藏
页数:4
相关论文
共 50 条
  • [41] CHEK2 1100delC is present in familial breast cancer cases of the Basque Country
    Cristina Martínez-Bouzas
    Elena Beristain
    Isabel Guerra
    Javier Gorostiaga
    Jose-Luis Mendizabal
    Jose-Luis De-Pablo
    Eva García-Alegría
    Arantza Sanz-Parra
    Maria-Isabel Tejada
    Breast Cancer Research and Treatment, 2007, 103 : 111 - 113
  • [42] CHEK2 1100delC is present in familial breast cancer cases of the Basque Country
    Martinez-Bouzas, Cristina
    Beristain, Elena
    Guerra, Isabel
    Gorostiaga, Javier
    Mendizabal, Jose-Luis
    De-Pablo, Jose-Luis
    Garcia-Alegria, Eva
    Sanz-Parra, Arantza
    Tejada, Maria-Isabel
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 103 (01) : 111 - 113
  • [43] Genetic and epigenetic analysis of CHEK2 in sporadic breast, colon, and ovarian cancers
    Williams, Louise H.
    Choong, David
    Johnson, Sandra A.
    Campbell, Ian G.
    CLINICAL CANCER RESEARCH, 2006, 12 (23) : 6967 - 6972
  • [44] Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care-Checking CHEK2
    Bychkovsky, Brittany L.
    Agaoglu, Nihat B.
    Horton, Carolyn
    Zhou, Jing
    Yussuf, Amal
    Hemyari, Parichehr
    Richardson, Marcy E.
    Young, Colin
    LaDuca, Holly
    McGuinness, Deborah L.
    Scheib, Rochelle
    Garber, Judy E.
    Rana, Huma Q.
    JAMA ONCOLOGY, 2022, 8 (11) : 1598 - 1606
  • [45] CHEK2 Founder Variants and Thyroid Cancer Risk
    Brock, Pamela
    Liynarachchi, Sandya
    Nieminen, Taina T.
    Chan, Carlos
    Kohlmann, Wendy
    Stout, Leigh Anne
    Yao, Song
    La Greca, Amanda
    Jensen, Kirk E.
    Kolesar, Jill M.
    Salhia, Bodour
    Gulhati, Pat
    Hicks, J. Kevin
    Ringel, Matthew D.
    THYROID, 2024, 34 (04) : 477 - 483
  • [46] CHEK2 variants associate with hereditary prostate cancer
    E H Seppälä
    T Ikonen
    N Mononen
    V Autio
    A Rökman
    M P Matikainen
    T L J Tammela
    J Schleutker
    British Journal of Cancer, 2003, 89 : 1966 - 1970
  • [47] CHEK2 variants associate with hereditary prostate cancer
    Seppälä, EH
    Ikonen, T
    Mononen, N
    Autio, V
    Rökman, A
    Matikainen, MP
    Tammela, TLJ
    Schleutker, J
    BRITISH JOURNAL OF CANCER, 2003, 89 (10) : 1966 - 1970
  • [48] Analysis of CHEK2 for ovarian cancer susceptibility.
    Baysal, BE
    DeLoia, JA
    Goodman, MT
    Willett-Brozick, JE
    Watson, P
    Birrer, MJ
    Gallion, HH
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 254 - 254
  • [49] Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?
    Cezary Cybulski
    Dominika Wokołorczyk
    Józef Kładny
    Grzegorz Kurzwaski
    Joanna Suchy
    Ewa Grabowska
    Jacek Gronwald
    Tomasz Huzarski
    Tomasz Byrski
    Bohdan Górski
    Tadeusz Dȩbniak
    Steven A Narod
    Jan Lubiński
    European Journal of Human Genetics, 2007, 15 : 237 - 241
  • [50] Time to check CHEK2 in families with breast cancer?
    Offit, Kenneth
    Garber, Judy Ellen
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) : 519 - 520